Vertex Energy, Inc. (NASDAQ:VTNR), an environmental services company that recycles industrial waste streams and off-specification commercial chemical products, announced its financial results for the fourth quarter and full year ended December 31, 2013. Revenue increased 20% to $162 million for the year ended 2013 compared with $135 million in 2012; Gross profit increased to $16.34 million, a 67% increase over the $9.79 million reported in 2012; and Net income increased 115% to $7.88 million for 2013 compared to 2012 net income of $3.66 million. Vertex Energy Inc (NASDAQ:VTNR) shares after opening at $5.94 on last trade day and at the end of the day closed at $6.00. Company price to sales ratio in past twelve months was calculated as 0.72 and price to cash ratio as 212.59. Vertex Energy Inc (NASDAQ:VTNR) showed a positive weekly performance of 61.29%.
Federated National Holding Co (NASDAQ:FNHC) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued to clients and investors on Monday, Analyst Ratings Network reports. The firm currently has a $16.70 price objective on the stock. Zacks‘s price objective suggests a potential upside of 5.43% from the company’s current price. Federated National Holding Co (NASDAQ:FNHC) shares advanced 0.53% in last trading session and ended the day on $17.00. FNHC return on equity ratio is recorded as 18.90% and its return on assets is 5.90%. Federated National Holding Co (NASDAQ:FNHC) yearly performance is 123.68%.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Peapack-Gladstone Financial Corp (NASDAQ:PGC) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the Company’s 2012 Long-Term Stock Incentive Plan. Peapack-Gladstone Financial Corp (NASDAQ:PGC) weekly performance is 12.96%. On last trading day company shares ended up $22.05. Peapack-Gladstone Financial Corp (NASDAQ:PGC) distance from 50-day simple moving average (SMA50) is 16.46%.
Endocyte, Inc. (NASDAQ:ECYT) shares skyrocketed 92.4% with the phase IIb TARGET study evaluating Vynfinit (vintafolide) in non-small cell lung cancer (:NSCLC) patients met its primary endpoint of improved progression free survival (PFS). Endocyte, Inc. (NASDAQ:ECYT) shares moved down -3.37% in last trading session and was closed at $27.22, while trading in range of $26.75 – $30.45. Endocyte, Inc. (NASDAQ:ECYT) year to date (YTD) performance is 154.87%.
Leave a Reply